--- title: "Cingulate (CING) news: offering and Nasdaq notice" url: "https://aibio.space/companies/cingulate/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "CING offering and Nasdaq notice news: Cingulate raises $5 million net through $5,480,000 unsecured promissory note. Cingulate Inc." --- CING Cingulate Inc. NASDAQ · United States # Cingulate (CING) news CING offering and Nasdaq notice news Distress · 2025-08-15 ## [Cingulate files NT 10-Q, citing management changes, for quarter ended June 30, 2025](https://aibio.space/news/cingulate-files-nt-10-q-citing-management-changes-quarter-ended-june/) The company says it needs more time to review its financial statements after recent changes in management. It expects to file its Form 10-Q within the five calendar day period under Rule 12b-25. ## Latest Cingulate news 1. 2025-08-15 Distress [Cingulate delays quarterly report after management changes](https://aibio.space/news/cingulate-delays-quarterly-report-after-management-changes/) Cingulate filed a late-filing notice for its report on the quarter ended June 30, 2025. It expects to file within the five-day extension period. 2. 2025-07-25 Financings [Cingulate reports unregistered share issuances to a lender in exchange for debt](https://aibio.space/news/cingulate-reports-unregistered-share-issuances-lender-exchange-debt/) Cingulate reported on July 25, 2025 that it issued common stock in three transactions with a lender, in exchange for part of the debt it owes, at $4.18 to $4.79 a share. The filing also covers a 7,538-share issuance to a service provider and a 30,000-share officer option grant. It names no bank or placement agent. 3. 2024-12-23 Debt Financing [Cingulate raises $5 million net through $5,480,000 unsecured promissory note](https://aibio.space/news/cingulate-raises-5-million-net-through-5-480-000-unsecured-promissory/) The note carries 9% annual interest and matures in 18 months. Cingulate says the money extends its cash runway into the fourth quarter of 2025. ## Cingulate at a glance - **Ticker**: CING - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $28.4 million ### Related companies - [LENZ Therapeutics](https://aibio.space/companies/lenz-therapeutics/) NASDAQ: LENZ - [Viridian Therapeutics](https://aibio.space/companies/viridian-therapeutics/) NASDAQ: VRDN - [Xilio Therapeutics](https://aibio.space/companies/xilio-therapeutics/) NASDAQ: XLO - [Aclaris Therapeutics](https://aibio.space/companies/aclaris-therapeutics/) NASDAQ: ACRS - [Supernus Pharmaceuticals](https://aibio.space/companies/supernus-pharmaceuticals/) NASDAQ: SUPN - [RegeneRx Biopharmaceuticals](https://aibio.space/companies/regenerx-biopharmaceuticals/) OTC: RGRX - [Sunshine Biopharma](https://aibio.space/companies/sunshine-biopharma/) NASDAQ: SBFM - [Protalix BioTherapeutics, Inc. (DE)](https://aibio.space/companies/protalix-biotherapeutics-de/) AMEX: PLX ### Also on NASDAQ - [CorMedix](https://aibio.space/companies/cormedix/) CRMD - [BlossomHill Therapeutics](https://aibio.space/companies/blossomhill-therapeutics/) BLSM - [Tempest Therapeutics](https://aibio.space/companies/tempest-therapeutics/) TPST - [BGM Group](https://aibio.space/companies/bgm/) BGM - [InMed Pharmaceuticals](https://aibio.space/companies/inmed-pharmaceuticals/) INM - [Sarepta Therapeutics](https://aibio.space/companies/sarepta-therapeutics/) SRPT ## Cingulate annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$9.8 million](https://www.sec.gov/Archives/edgar/data/1862150/000149315226010882/) | [$9.4 million](https://www.sec.gov/Archives/edgar/data/1862150/000149315226010882/) | | Net income (loss) | [-$22.4 million](https://www.sec.gov/Archives/edgar/data/1862150/000149315226010882/) | [-$16.6 million](https://www.sec.gov/Archives/edgar/data/1862150/000149315226010882/) | | Cash from operations | [-$17.2 million](https://www.sec.gov/Archives/edgar/data/1862150/000149315226010882/) | [-$18.5 million](https://www.sec.gov/Archives/edgar/data/1862150/000149315226010882/) | | Cash and equivalents | [$11.0 million](https://www.sec.gov/Archives/edgar/data/1862150/000149315226037606/) | [$12.2 million](https://www.sec.gov/Archives/edgar/data/1862150/000149315226010882/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $28.4 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Cingulate Has Cingulate raised money recently? Our latest story on this, dated Dec 23, 2024: "Cingulate raises $5 million net through $5,480,000 unsecured promissory note". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/cingulate-raises-5-million-net-through-5-480-000-unsecured-promissory/). Has Cingulate received a Nasdaq deficiency notice? Our latest story on this, dated Aug 15, 2025: "Cingulate delays quarterly report after management changes". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/cingulate-delays-quarterly-report-after-management-changes/). What is the ticker symbol of Cingulate? Cingulate Inc. trades under the ticker CING on NASDAQ. Where is Cingulate listed? Cingulate Inc. is listed on NASDAQ. What is the SEC CIK of Cingulate? The SEC Central Index Key (CIK) for Cingulate Inc. is 1862150. Its filings are on SEC EDGAR. How many shares does Cingulate have outstanding? 14,541,826 shares as of 2026-08-12, per the cover page of its 10-Q filed 2026-08-13. Which country or territory is Cingulate listed under? Our directory records Cingulate Inc. under United States. What does Cingulate do? Our directory classifies Cingulate Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Cingulate? The ISIN recorded for Cingulate Inc. is US17248W3034. Does aibio.space cover Cingulate? aibio.space lists Cingulate Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Cingulate incorporated? SEC records list its state or country of incorporation as DE. Is Cingulate profitable? Cingulate Inc. reported a net loss of $22.4 million for the fiscal year ended Dec 31, 2025, and used $17.2 million of cash in operations, per its annual report to the SEC. How much does Cingulate spend on research and development? $9.8 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Cingulate have? $28.4 million in cash at Jun 30, 2026, per its 10-Q. What is the latest Cingulate (CING) stock news? Our latest story on Cingulate, dated Aug 15, 2025: "Cingulate files NT 10-Q, citing management changes, for quarter ended June 30, 2025". The company says it needs more time to review its financial statements after recent changes in management. It expects to file its Form 10-Q within the five calendar day period under Rule 12b-25. [Source](https://aibio.space/news/cingulate-files-nt-10-q-citing-management-changes-quarter-ended-june/). ## Investor discussion: Cingulate Members talk about Cingulate (CING). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Cingulate, newest first. Each line links the filing it comes from. 1. 2026-03-24 Financings Reported a financing. SEC Form 8-K (Items 1.01,5.07). [Source](https://www.sec.gov/Archives/edgar/data/1862150/000149315226012417/form8-k.htm) 2. 2026-02-17 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,5.02,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1862150/000149315226006942/ex99-1.htm) 3. 2026-01-28 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1862150/000149315226004030/form8-k.htm) 4. 2026-01-02 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02). [Source](https://www.sec.gov/Archives/edgar/data/1862150/000149315226000142/form8-k.htm) 5. 2025-11-10 Financings Reported a financing. SEC Form 8-K (Items 1.01,2.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1862150/000149315225021410/ex99-1.htm) 6. 2025-09-05 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02). [Source](https://www.sec.gov/Archives/edgar/data/1862150/000149315225012753/form8-k.htm) 7. 2025-08-15 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1862150/000164117225024288/formnt10-q.htm) 8. 2025-07-22 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1862150/000164117225020618/form8-k.htm) 9. 2025-06-11 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1862150/000164117225014621/form8-k.htm) 10. 2025-05-13 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02). [Source](https://www.sec.gov/Archives/edgar/data/1862150/000164117225009989/form8-k.htm) 11. 2025-04-25 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1862150/000164117225006260/formdef14a.htm) 12. 2025-04-15 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1862150/000164117225004851/formpre14a.htm) 13. 2024-12-23 Financings Reported a financing. SEC Form 8-K (Items 1.01,2.03,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1862150/000149315224051196/ex99-1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:CING on TradingView](https://www.tradingview.com/symbols/NASDAQ-CING/). ## SEC filings and registration - **SEC name**: Cingulate Inc. - **CIK**: 1862150 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: CING (Nasdaq), CINGW (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 1901 W. 47TH PLACE, KANSAS CITY, KS, 66205 - **Phone**: (913) 942-2300 - **Shares outstanding**: 14,541,826 as of 2026-08-12 (10-Q filed 2026-08-13) - **Former names**: Cingulate Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1862150/000149315226045527/form8-k.htm) filed 2026-10-02 - [10-Q](https://www.sec.gov/Archives/edgar/data/1862150/000149315226037606/form10-q.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1862150/000149315226037605/form8-k.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1862150/000149315226034402/form8-k.htm) filed 2026-07-23 - [8-K](https://www.sec.gov/Archives/edgar/data/1862150/000149315226033115/form8-k.htm) filed 2026-07-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1862150/000149315226031668/form8-k.htm) filed 2026-07-02 - [8-K](https://www.sec.gov/Archives/edgar/data/1862150/000149315226028815/form8-k.htm) filed 2026-06-16 - [8-K](https://www.sec.gov/Archives/edgar/data/1862150/000149315226026760/form8-k.htm) filed 2026-06-02 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001862150), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Cingulate Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker CING, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Cingulate Inc. - **Ticker**: CING - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US17248W3034 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-CING/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/cingulate/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Cingulate (CING) news: offering and Nasdaq notice", 2026-10-31, https://aibio.space/companies/cingulate/